



800 Gateway Boulevard
South San Francisco, CA 94080
T (650) 877 0900 F (650) 877 8370

Thursday, January 03, 2002

Jeremy Talbott
Patent Portfolio Manager
VERNALIS LIMITED
613 Reading Road
Oakdene Court
Winnersh, Workingham Berkshire
UK RG14 5UA

Re: Patent Term Extension Application Under 35 U.S.C. § 156 Based on Regulatory Review of FROVA™

Dear Mr. Talbott:

Elan Pharmaceuticals hereby authorizes Vernalis Limited to rely on Elan's activities before the U.S. Food and Drug Administration in seeking approval for FROVA™ (frovatriptan succinate, NDA 21-006), in order to file an application for patent term extension under 35 U.S.C. § 156 based on the regulatory review of FROVA™.

Sincerely,

A handwritten signature in black ink, appearing to read "Eugene Thorsett".

Eugene Thorsett
Vice President, Chemical Sciences